Texas Children’s Hospital Center for Vaccine Development (CVD)

Recombinant Protein COVID-19 Vaccine Technology

Since 2011, the BCM-Texas Children’s CVD has been developing recombinant protein coronavirus vaccines for SARS and MERS, and in 2020 developed the first recombinant protein COVID-19 through microbial fermentation in yeast. The technology has been transferred to 4 entities to date: India (Biological E, CORBEVAX), Indonesia (BioFarma, CORONAVAC), Bangladesh (Incepta) and Botswana (ImmunityBio). In India and Indonesia, more than 100 million doses of these vaccines have been administered. CORBEVAX has also been authorized as an adult heterologous booster. To date there are 8 scientific publications about laboratory development of the BCM-Texas Children’s CVD recombinant protein COVID-19 vaccine (in addition to 5 others on SARS/MERS (not shown), and 3 on the clinical trials see below):

**Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate**

**Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate**

**Whole Inactivated Virus and Protein-Based COVID-19 Vaccines**

**SARS‑CoV-2 RBD219-N1C1:** **A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice**

**Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern**

**Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1**

**Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity**

**A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates**

The published results from the clinical trials performed by Biological E Ltd. can be found in the following articles and Medrxiv Preprints:

Share this:

Like this: